Press releases

•    Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease 
•    Cash runway extended into 2026
•    Evan Ballantyne joins Hansa Biopharma as Chief Financial Officer

Company expects revenue of SEK 54m including product sales of SEK 48m - an increase of 10% versus the prior quarter and a 234% increase versus Q1 2023

Q1 2024 is the first time Hansa has delivered two consecutive quarters of strong revenue and growth

Company delivered significant progress across commercial and R&D priorities

· Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging results from first-in-human trial of HNSA-5487
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMD

· Strong revenue generation in Q4 2023, including SEK 43m in Idefirix[®] product sales supported by growth in new markets such as U.K., Germany, and Spain
· Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing
· Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SR…

Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared to standard of care